Peptidylprolyl isomerase A pseudogene 34 (PPIAP34)

Peptidylprolyl isomerase A pseudogene 34 (PPIAP34) is a genomic sequence related to the peptidylprolyl isomerase A (PPIA) gene but is considered a pseudogene, meaning it does not encode a functional protein[1][2]. PPIAP34 may arise by gene duplication or retrotransposition and typically accumulates disabling mutations (e.g., truncations, frameshifts) that prevent protein translation[2]. While certain pseudogenes can produce non-coding RNAs with regulatory functions, there is no evidence that PPIAP34 participates in such activity, and thus it has no direct biological functions. It does not play a role in protein folding, catalysis, signaling, or serve as a therapeutic target, and should not be confused with PPIA (cyclophilin A), which is an active enzyme involved in key cellular processes and disease biology[4][7][12][15]. PPIAP34 has no known disease associations directly attributed to it; while general pseudogenes can have regulatory effects in cancer and other conditions, those roles are context dependent and no data is available for this specific pseudogene. As PPIAP34 does not produce a protein, it cannot serve as a drug target, and consequently there are no interacting drugs. This pseudogene is not used in clinical biomarker panels, and there are no relevant safety concerns as it is not therapeutically exploited. The canonical functional gene, peptidylprolyl isomerase A (PPIA), is a cytosolic enzyme involved in protein folding, immune regulation, and is a recognized drug target[4][7][12][15]. PPIAP34 is distinct and not involved in these activities. If the intention was to refer to PPIA rather than its pseudogene, the correct canonical name is "Peptidylprolyl isomerase A" (PPIA)[12]. In summary, PPIAP34 is not a functional molecular target, contains no therapeutic or diagnostic relevance, and should not be treated as such for structured biomedical purposes[1][2].

none; drugs do not target pseudogenes directly.